Ascendis Pharma (Brazil) Today
| A1SN34 Stock | BRL 58.44 0.00 0.00% |
Performance15 of 100
| Odds Of DistressLess than 28
|
Ascendis Pharma is trading at 58.44 as of the 30th of January 2025, a No Change since the beginning of the trading day. The stock's open price was 58.44. Ascendis Pharma has about a 28 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 31st of December 2024 and ending today, the 30th of January 2025. Click here to learn more.
Moving against Ascendis Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Ascendis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Ascendis Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Ascendis Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Ascendis Pharma AS (A1SN34) is traded on Sao Paulo Exchange in Brazil and employs 639 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 34.39 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ascendis Pharma's market, we take the total number of its shares issued and multiply it by Ascendis Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Ascendis Pharma AS operates under Healthcare sector and is part of Biotechnology industry. The entity has 57.03 M outstanding shares.
Ascendis Pharma generates negative cash flow from operations
Check Ascendis Pharma Probability Of Bankruptcy
Ascendis Pharma AS Risk Profiles
Although Ascendis Pharma's alpha and beta are two of the key measurements used to evaluate Ascendis Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.6369 | |||
| Standard Deviation | 1.64 | |||
| Variance | 2.69 | |||
| Risk Adjusted Performance | 0.1401 |
Ascendis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Ascendis Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run ETF Categories Now
ETF CategoriesList of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
| All Next | Launch Module |
Ascendis Pharma Corporate Management
Elected by the shareholders, the Ascendis Pharma's board of directors comprises two types of representatives: Ascendis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascendis. The board's role is to monitor Ascendis Pharma's management team and ensure that shareholders' interests are well served. Ascendis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascendis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Flemming Jensen | VP Quality | Profile | |
| Scott Smith | Sr CFO | Profile | |
| Michael LLM | Chief VP | Profile | |
| Jan Mikkelsen | CEO and President | Profile | |
| Birgitte MD | Sr Affairs | Profile | |
| Timothy Lee | Director Relations | Profile | |
| Lotte Sonderbjerg | Sr Officer | Profile |
Additional Information and Resources on Investing in Ascendis Stock
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.